相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension A Double-Blind Placebo-controlled Clinical Trial
R. James White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents
Vallerie V. McLaughlin et al.
CHEST (2020)
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Kenichi Yanaka et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Olivier Sitbon et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy
Georg Hansmann et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
Garance Kopp et al.
FRONTIERS IN MEDICINE (2020)
Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
Abraham Rothman et al.
PULMONARY CIRCULATION (2020)
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study
Adaani Frost et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2019)
Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro
Shunji Imai et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial
Olivier Sitbon et al.
LANCET RESPIRATORY MEDICINE (2019)
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Maurice Beghetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Risk stratification and medical therapy of pulmonary arterial hypertension
Nazzareno Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Nathan Holthaus et al.
PULMONARY CIRCULATION (2019)
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag
Margaux Boehler et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag
Carmela Gnerre et al.
XENOBIOTICA (2018)
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
J. Gerry Coghlan et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
Ioana R. Preston et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2018)
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
Sherif M. Fanous et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
Martin Koestenberger et al.
PULMONARY CIRCULATION (2018)
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist
Priska Kaufmann et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
Pierre-Eric Juif et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Sean Gaine et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential
John Gatfield et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Single-Center Experience Using Selexipag in a Pediatric Population
Roberto Gallotti et al.
PEDIATRIC CARDIOLOGY (2017)
An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
Marcin Kurzyna et al.
BMC PULMONARY MEDICINE (2017)
First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
Lianne M. Geerdink et al.
PULMONARY CIRCULATION (2017)
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects
Shirin Bruderer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects
Shirin Bruderer et al.
CLINICAL THERAPEUTICS (2016)
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
Caroline O'Connell et al.
DRUG SAFETY (2016)
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
Priska Kaufmann et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2015)
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Vallerie McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Tetsuo Asaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
N. Galie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Olivier Sitbon et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects
Shirin Bruderer et al.
PHARMACOLOGY (2014)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
Zhi-Cheng Jing et al.
CIRCULATION (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Victor E. Tapson et al.
CHEST (2012)
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
David Montani et al.
EUROPEAN HEART JOURNAL (2010)
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial
Jagdish Hiremath et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2010)
Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function
Keith Morrison et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2yl)(isopropyl) amino]butoxy}-N-(methylsulfonyl)acetamide(NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy} acetic acid (MRE-269), on rat pulmonary artery
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial
N. Galie et al.
LANCET (2008)
Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists
Tetsuo Asaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
Vallerie V. McLaughlin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Bosentan therapy in patients with Eisenmenger syndrome - A multicenter, double-blind, randomized, placebo-controlled study
Nazzareno Galie et al.
CIRCULATION (2006)
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension - A prospective, multicenter, open-label, 12-week trial
VF Tapson et al.
CHEST (2006)
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
M Gomberg-Maitland et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
O Sitbon et al.
CIRCULATION (2005)
Drug therapy: Treatment of pulmonary arterial hypertension
M Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Beraprost therapy for pulmonary arterial hypertension
RJ Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial
N Galiè et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
DB Badesch et al.
ANNALS OF INTERNAL MEDICINE (2000)
分享论文
